

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

09/972,758

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, C07K 14/705, A61K 38/17, C07K 16/28, C12Q 1/68		A1	(11) International Publication Number: WO 98/48016 (43) International Publication Date: 29 October 1998 (29.10.98)
<p>(21) International Application Number: PCT/US98/07830</p> <p>(22) International Filing Date: 17 April 1998 (17.04.98)</p> <p>(30) Priority Data: 08/845,566 24 April 1997 (24.04.97) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/845,566 (CIP) Filed on 24 April 1997 (24.04.97)</p> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94702 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US).</p> <p>(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p>		<p>(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: EDG-1-LIKE RECEPTOR</p> <p>(57) Abstract</p> <p>The present invention provides a new edg-1 like receptor (NEDG) and polynucleotides which identify and encode NEDG. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of NEDG.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

EDG-1-LIKE RECEPTOR

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of a new edg-1-like receptor and to the use of these sequences in the diagnosis, prevention, and treatment of cancers and disorders associated with cellular growth and differentiation.

BACKGROUND ART

Cellular early response genes are a class of genes whose transcription is activated within minutes of exposure of cells to stimuli. When quiescent cells are stimulated, the early-response genes are rapidly induced. These genes alter target gene expression by coupling short-term signals induced by extracellular stimuli to long-term changes in cellular phenotype. They encode proteins that induce phenotypic alterations by modulating the transcription rates of genes, and have been shown to have critical roles in the control of growth and differentiation (Lau, L. And Nathans, D. (1987) Proc. Natl. Acad. Sci. 84:1182-1186).

Extracellular stimuli which induce early response genes include growth factors, phorbol esters, okadaic acid, protein synthesis inhibitors, toxins, and abrupt changes in temperature, pH, and oxygen. The stimulus activates cell surface receptors and membrane bound molecules which initiate signaling cascades that induce the transcription of early response genes. These early response genes include the genes for cytokines; *fos*, *myc*, *jun*, the edg-1 receptor, and nuclear receptors, all of which have roles in cellular proliferation and differentiation.

The edg-1 receptor is an immediate-early response gene that has been characterized in rats and humans and is induced by stimuli that initiate cellular differentiation. The edg-1 gene product is a G-protein-coupled receptor classified as an orphan receptor because its' ligand is unknown. It shares features with other seven transmembrane proteins including seven hydrophobic domains which span the plasma membrane and form a bundle of antiparallel α helices. Stimulation of these receptors by agonists activates the receptor and allows it to interact with an intracellular G-protein complex. The G protein complex activates a variety of second messenger molecules which regulate signaling pathways and modulate cellular responses (Lee, M. J. et al (1996) J. Biol. Chem. 271:11272-11279).

The human edg-1 receptor was first isolated by Hla, T. and Maciag, T. (1990, J. Biol. Chem. 265: 9308-9313) when they were screening phorbol 12-myristate 13-acetate (PMA) treated endothelial cells for induced early gene transcripts involved in cell differentiation. Endothelial cell differentiation is a key factor in the initiation of angiogenesis. This is a process

by which new vascular networks are formed from pre-existing capillaries and is necessary for growth, tissue remodeling, and wound repair. Physiologically, it is essential for embryogenesis, tissue and organ development, ovulation, and corpus luteum formation. In addition, it occurs during the progression of various pathological conditions such as diabetic retinopathy.

5 rheumatoid arthritis, occlusive vascular diseases, and cancers, where angiogenesis provides the nutrients and oxygen for growth of solid tumors. PMA is a tumor promoter which alters the growth of endothelial cells *in vitro* and stimulates their differentiation into capillary-like tubules. Many of the early endothelial cell genes induced by PMA treatment have a role in cell differentiation and, as such, determine the molecular events involved in the control of cellular 10 growth and differentiation.

The discovery of new edg-1-like receptor and the polynucleotides encoding it satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention and treatment of cancers and disorders of cellular growth and differentiation.

DISCLOSURE OF THE INVENTION

15 The present invention features a new edg-1-like receptor hereinafter designated NEDG and characterized as having similarity to human edg-1.

Accordingly, the invention features a substantially purified new edg-1 like receptor having the amino acid sequence shown in SEQ ID NO:1.

One aspect of the invention features isolated and substantially purified polynucleotides 20 that encode NEDG. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2.

The invention also relates to a polynucleotide sequence comprising the complement of SEQ ID NO:2 or variants thereof. In addition, the invention features polynucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2.

25 The invention additionally features nucleic acid sequences encoding fragments, portions or complement of the polynucleotides encoding NEDG, as well as expression vectors and host cells comprising said polynucleotides. The invention also features an antibody to NEDG, and a pharmaceutical composition comprising substantially purified NEDG. The invention features agonists and antagonists of NEDG. The invention also features a method for treating a disorder 30 associated with decreased NEDG by administering NEDG, and a method for treating a disorder associated with increased NEDG by administering an antagonist to NEDG.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A, 1B, 1C, 1D, and 1E show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of NEDG. The alignment was produced using MacDNASIS PRO™ software (Hitachi Software Engineering Co., Ltd., San Bruno, CA).

Figures 2A and 2B show the amino acid sequence alignments between NEDG (SEQ ID NO:1) and human edg-1 (GI 181948, SEQ ID NO:3). The alignment was produced using the multisequence alignment program of DNASTAR™ software (DNASTAR Inc, Madison WI).

Figures 3A and 3B show the hydrophobicity plots (MacDNASIS PRO software) for NEDG and human edg-1, respectively; the positive X axis reflects amino acid position, and the negative Y axis, hydrophobicity.

10

MODES FOR CARRYING OUT THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide, or

polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or complement or antisense strand. Similarly, "amino acid sequence" as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragments or portions thereof, and to naturally occurring or synthetic molecules.

Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms, such as "polypeptide" or "protein" are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

10 "Peptide nucleic acid", as used herein, refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine, and an amino group have been added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary strand of nucleic acid (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

NEDG, as used herein, refers to the amino acid sequences of substantially purified NEDG 15 obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

"Consensus", as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, or which has been extended using XL-PCR™ (Perkin 20 Elmer, Norwalk, CT) in the 5' and/or the 3' direction and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte clone using the GELVIEW™ Fragment Assembly system (GCG, Madison, WI), or which has been both extended and assembled.

A "variant" of NEDG, as used herein, refers to an amino acid sequence that is altered by 25 one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, 30 inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

A "deletion", as used herein, refers to a change in either amino acid or nucleotide

sequence in which one or more amino acid or nucleotide residues, respectively, are absent.

An "insertion" or "addition", as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid or nucleotide residues, respectively, as compared to the naturally occurring molecule.

5 A "substitution", as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

The term "biologically active", as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic NEDG, 10 or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "agonist", as used herein, refers to a molecule which, when bound to NEDG, causes a change in NEDG which modulates the activity of NEDG. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to NEDG.

15 The terms "antagonist" or "inhibitor", as used herein, refer to a molecule which, when bound to NEDG, blocks or modulates the biological or immunological activity of NEDG. Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to NEDG.

The term "modulate", as used herein, refers to a change or an alteration in the biological 20 activity of NEDG. Modulation may be an increase or a decrease in protein activity, a change in binding characteristics, or any other change in the biological, functional or immunological properties of NEDG.

The term "mimetic", as used herein, refers to a molecule, the structure of which is developed from knowledge of the structure of NEDG or portions thereof and, as such, is able to 25 effect some or all of the actions of NEDG-like molecules.

The term "derivative", as used herein, refers to the chemical modification of a nucleic acid encoding NEDG or the encoded NEDG. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a polypeptide which retains essential biological characteristics of the natural molecule.

30 The term "substantially purified", as used herein, refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which

they are naturally associated.

"Amplification" as used herein refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

The term "hybridization", as used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term "hybridization complex", as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary 10 G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., membranes, filters, chips, 15 pins or glass slides to which cells have been fixed for in situ hybridization).

The terms "complementary" or "complementarity", as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, for the sequence "A-G-T" binds to the complementary sequence "T-C-A".

Complementarity between two single-stranded molecules may be "partial", in which only some 20 of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands.

25 The term "homology", as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence is one that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid; it is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined 30 using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous sequence or probe to

the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks 5 even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base 10 composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.), and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

15 The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about $T_m - 5^\circ\text{C}$ (5°C below the melting temperature (T_m) of the probe) to about 20°C to 25°C below T_m . As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

20 The term "antisense", as used herein, refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense or complementary molecules may be produced by any method, including synthesis by ligating the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a 25 complementary strand. Once introduced into a cell, this transcribed strand combines with natural sequences produced by the cell to form duplexes. These duplexes then block either the further transcription or translation. In this manner, mutant phenotypes may be generated. The designation "negative" is sometimes used in reference to the antisense or complement strand, and "positive" is sometimes used in reference to the sense strand.

30 The term "portion", as used herein, with regard to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein

"comprising at least a portion of the amino acid sequence of SEQ ID NO:1" encompasses the full-length human NEDG and fragments thereof.

"Transformation", as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using various 5 methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed and may include, but is not limited to, viral infection, electroporation, lipofection, and particle bombardment. Such "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an 10 autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

The term "antigenic determinant", as used herein, refers to that portion of a molecule that makes contact with a particular antibody (i.e., an epitope). When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the 15 production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The terms "specific binding" or "specifically binding", as used herein, in reference to the 20 interaction of an antibody and a protein or peptide, mean that the interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) on the protein; in other words, the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the 25 antibody will reduce the amount of labeled A bound to the antibody.

The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding NEDG or fragments thereof may comprise a cell, chromosomes isolated from a cell (e.g., a spread of metaphase chromosomes), genomic DNA (in solution or bound to a solid support such as for Southern analysis), RNA (in solution or bound to 30 a solid support such as for northern analysis), cDNA (in solution or bound to a solid support), an extract from cells or a tissue, and the like.

The term "correlates with expression of a polynucleotide", as used herein, indicates that

the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2 by northern analysis is indicative of the presence of mRNA encoding NEDG in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

“Alterations” in the polynucleotide of SEQ ID NO:2, as used herein, comprise any alteration in the sequence of polynucleotides encoding NEDG including deletions, insertions, and point mutations that may be detected using hybridization assays. Included within this definition is the detection of alterations to the genomic DNA sequence which encodes NEDG (e.g., by alterations in the pattern of restriction fragment length polymorphisms capable of hybridizing to SEQ ID NO:2), the inability of a selected fragment of SEQ ID NO:2 to hybridize to a sample of genomic DNA (e.g., using allele-specific oligonucleotide probes), and improper or unexpected hybridization, such as hybridization to a locus other than the normal chromosomal locus for the polynucleotide sequence encoding NEDG (e.g., using fluorescent *in situ* hybridization [FISH] to metaphase chromosomes spreads).

As used herein, the term “antibody” refers to intact molecules as well as fragments thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind NEDG polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal can be derived from the transition of RNA or synthesized chemically, and can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

The term “humanized antibody”, as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

25 THE INVENTION

The invention is based on the discovery of a new edg-1 like protein, (NEDG), the polynucleotides encoding NEDG, and the use of these compositions for the diagnosis, prevention, or treatment of disorders associated with expression of NEDG, including cancer.

Nucleic acids encoding the human NEDG of the present invention were first identified in 30 Incyte Clone 144690 from the tumor cDNA library TLYMNOR01 through a computer search for amino acid sequence alignments. The complete nucleotide sequence, SEQ ID NO:2, was derived from extension of Incyte clone 144690 (TLYMNOR01).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figures 1A, 1B, 1C, 1D and 1E. NEDG is 509 amino acids in length and has chemical and structural homology with human edg-1 (SEQ ID NO:3). In particular, NEDG shares 34% identity with human edg-1. As shown in Figures 2A and 2B,

5 NEDG and human edg-1 contain an Asn glycosylation site at N₃₀ and have conserved cysteines at positions 58, 169, 186, 193, and 208. As illustrated by Figures 3A and 3B, NEDG and human edg-1 have rather similar hydrophobicity plots. Northern analysis shows the expression of this sequence in various libraries, a majority of which are associated with proliferating tissues, including cancers.

10 The invention also encompasses NEDG variants. A preferred NEDG variant is one having at least 80%, and more preferably 90%, amino acid sequence identity to the NEDG amino acid sequence (SEQ ID NO:1). A most preferred NEDG variant is one having at least 95% amino acid sequence identity to SEQ ID NO:1.

15 The invention also encompasses polynucleotides which encode NEDG. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of NEDG can be used to generate recombinant molecules which express NEDG. In a particular embodiment, the invention encompasses the polynucleotide comprising the nucleic acid sequence of SEQ ID NO:2 as shown in Figures 1A, 1B, 1C, 1D and 1E.

20 It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding NEDG, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the 25 nucleotide sequence of naturally occurring NEDG, and all such variations are to be considered as being specifically disclosed.

25 Although nucleotide sequences which encode NEDG and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring NEDG under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide 30 sequences encoding NEDG or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular

codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding NEDG and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

5 The invention also encompasses production of DNA sequences, or portions thereof, which encode NEDG and its derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding
10 NEDG or any portion thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, under various conditions of stringency. Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex or probe, as taught in Wahl, G.M. and S.L.
15 Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511), and may be used at a defined stringency.

Altered nucleic acid sequences encoding NEDG which are encompassed by the invention include deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent NEDG. The encoded protein may also contain
20 deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent NEDG. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of NEDG is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively
25 charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.

Also included within the scope of the present invention are alleles of the genes encoding NEDG. As used herein, an "allele" or "allelic sequence" is an alternative form of the gene which
30 may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one, or many allelic forms. Common mutational changes which give rise to

alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

- Methods for DNA sequencing which are well known and generally available in the art 5 may be used to practice any embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg, MD).
- 10 Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI 377 DNA sequencers (Perkin Elmer).

The nucleic acid sequences encoding NEDG may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream 15 sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the 20 same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). The primers may 25 be designed using OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

- 30 Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119). In this method, multiple

restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before performing PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J.D. 5 et al. (1991; Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk in genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they 10 will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into the 5' and 3' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to 15 analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g. Genotyper™ and Sequence 20 Navigator™, Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof 25 which encode NEDG, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of NEDG in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express NEDG.

30 As will be understood by those of skill in the art, it may be advantageous to produce NEDG-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate

of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

- The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter NEDG encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding NEDG may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of NEDG activity, it may be useful to encode a chimeric NEDG protein that can be recognized by a commercially available antibody.

- 15 A fusion protein may also be engineered to contain a cleavage site located between the NEDG encoding sequence and the heterologous protein sequence, so that NEDG may be cleaved and purified away from the heterologous moiety.

- 15 In another embodiment, sequences encoding NEDG may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, Horn, T. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of NEDG, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

- 25 The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence of NEDG, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active NEDG, the nucleotide sequences encoding NEDG or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

5 Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding NEDG and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, 10 Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.

A variety of expression vector/host systems may be utilized to contain and express sequences encoding NEDG. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression 15 vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

The "control elements" or "regulatory sequences" are those non-translated regions of the 20 vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid 25 lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from 30 mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding NEDG, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for NEDG. For example, when large quantities of NEDG are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional E.
5 coli cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding NEDG may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Promega, Madison, WI) may also be used to express foreign polypeptides as
10 fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

15 In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) Methods Enzymol. 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding NEDG may be driven by any of a number of promoters. For example, viral promoters such as the
20 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be
25 introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.

An insect system may also be used to express NEDG. For example, in one such system, 30 Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding NEDG may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed

under control of the polyhedrin promoter. Successful insertion of NEDG will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which NEDG may be expressed (Engelhard, E.K. et al. (1994) Proc. Nat. Acad. Sci.

5 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding NEDG may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may 10 be used to obtain a viable virus which is capable of expressing NEDG in infected host cells (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of 15 sequences encoding NEDG. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding NEDG, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation 20 codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system 25 which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which 30 cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational

activities, may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express NEDG may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes which can be employed in tk⁻ or aprt⁻ cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding NEDG is inserted within a marker gene sequence, recombinant cells containing sequences encoding NEDG can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding NEDG under the control of a single promoter. Expression of the marker gene in response to induction or selection

usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the nucleic acid sequence encoding NEDG and express NEDG may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and 5 protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding NEDG can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or portions or fragments of polynucleotides encoding NEDG. Nucleic acid amplification based assays involve the use of 10 oligonucleotides or oligomers based on the sequences encoding NEDG to detect transformants containing DNA or RNA encoding NEDG. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides, which can be used as a probe or amplier.

15 A variety of protocols for detecting and measuring the expression of NEDG, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on NEDG is preferred, but a 20 competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. et al. (1983; *J. Exp. Med.* 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled 25 hybridization or PCR probes for detecting sequences related to polynucleotides encoding NEDG include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding NEDG, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an 30 appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH).

Suitable reporter molecules or labels, which may be used, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding NEDG may be cultured under 5 conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode NEDG may be designed to contain signal sequences which direct secretion of NEDG through a prokaryotic or eukaryotic cell membrane.

10 Other recombinant constructions may be used to join sequences encoding NEDG to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the

15 FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and NEDG may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing NEDG and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage

20 site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3:263-281) while the enterokinase cleavage site provides a means for purifying NEDG from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453).

25 In addition to recombinant production, fragments of NEDG may be produced by direct peptide synthesis using solid-phase techniques Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of NEDG may be chemically

30 synthesized separately and combined using chemical methods to produce the full length molecule.

THERAPEUTICS

Based on the chemical and structural homology between NEDG (SEQ ID NO:1) and human edg-1 (SEQ ID NO:3), NEDG functions as an early response gene and has the structural characteristics of a G protein-coupled receptor. NEDG may enable cells to respond to external stimuli, modify growth, and initiate differentiation. Northern analysis indicates that NEDG is 5 associated with proliferating tissues, including cancers, and may play a role in modulating cell growth and differentiation.

Therefore, in one embodiment, NEDG or a fragment or derivative thereof may be added to cells to stimulate cell proliferation. In particular, NEDG may be added to a cell or cells *in vivo* using delivery mechanisms such as liposomes, viral based vectors, or electroinjection for the 10 purpose of promoting regeneration or differentiation of the cell or cells. In addition, NEDG may be added to a cell, cell line, tissue or organ culture *in vitro* or *ex vivo* to stimulate cell proliferation for use in autologous or heterologous transplantation. In some cases, the cell will have been selected for its ability to fight an infection or a cancer or to correct a genetic defect in a disease such as sickle cell anemia, β thalassemia, Huntington's chorea, cystic fibrosis, etc.

15 In another embodiment, NEDG or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder of abnormal cell growth and differentiation. These disorders include, but are not limited to, Alzheimer's disease, aberrant corpus luteum formation, osteoarthritis, osteoporosis, anovulation, Parkinson's disease and rheumatoid arthritis. In addition, NEDG or a fragment or derivative thereof may be administered to a subject to treat a 20 disorder which results in damage to cells, such as myocardial infarction, arteriosclerosis, peripheral vascular disease, stroke, and various types of ischemia.

In another embodiment, a vector capable of expressing NEDG, or a fragment or a derivative thereof, may also be administered to a subject to treat or prevent the disorders of abnormal cell growth and differentiation listed above.

25 In another embodiment, agonists of NEDG may be administered to a subject to treat or prevent the disorders of abnormal cell growth and differentiation listed above.

In another embodiment, antagonists or inhibitors of NEDG may be administered to a subject to treat or prevent a disorder of excessive cell proliferation. In particular such cell proliferation includes that which occurs in cancer. Such types of cancer include, but are not 30 limited to, adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma and particularly cancers of the adrenal gland, bladder, bone, brain, breast, cervix, esophagus, gastrointestinal tract, heart, kidney, liver, lung, ovaries, pancreas, parathyroid.

pituitary gland, prostate, salivary gland, spleen, stomach, thymus, thyroid, testes, and uterus. Other disorders include, but are not limited to, adult respiratory distress syndrome, allergies, ankylosing spondylitis, asthma, atherosclerosis, arteriosclerosis, bronchitis, dermatomyositis, diabetic retinopathy, hypereosinophilia, neurofibromatosis, polymyositis, and rheumatoid

5 arthritis.

In another embodiment, a vector expressing the complement or antisense of the polynucleotide encoding NEDG may be administered to a subject to treat or prevent the disorders listed above. In one aspect, antibodies which are specific for NEDG may be used directly as an antagonist, or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent

10 to cells or tissue which express NEDG.

In other embodiments, any of the therapeutic proteins, antagonists, antibodies, agonists, antisense or complement sequences or vectors described above may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to

15 conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above.

Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

Antagonists or inhibitors of NEDG may be produced using methods which are generally

20 known in the art. In particular, purified NEDG may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind NEDG.

Antibodies to NEDG may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing

25 antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with NEDG or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to,

30 Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and

Corynebacterium parvum are especially preferable.

It is preferred that the peptides, fragments, or oligopeptides used to induce antibodies to NEDG have an amino acid sequence consisting of at least five amino acids, and more preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of NEDG amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to NEDG may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; Takeda, S. et al. (1985) *Nature* 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce NEDG-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton D.R. (1991) *Proc. Natl. Acad. Sci.* 88:11120-3).

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci.* 86: 3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299).

Antibody fragments which contain specific binding sites for NEDG may also be generated. For example, such fragments include, but are not limited to, the F(ab')2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal

Fab fragments with the desired specificity (Huse, W.D. et al. (1989) *Science* 254:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between NEDG and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering NEDG epitopes is preferred, but a competitive binding assay may also be employed (Maddox, *supra*).

In another embodiment of the invention, the polynucleotides encoding NEDG, or any fragment thereof, or antisense or complement molecules, may be used for therapeutic purposes. In one aspect, antisense or complement to the polynucleotide encoding NEDG may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding NEDG. Thus, antisense or complement molecules may be used to modulate NEDG activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense or complement oligomers or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding NEDG.

Expression vectors derived from retro viruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense molecules complementary to the polynucleotides of the gene encoding NEDG. These techniques are described both in Sambrook et al. (*supra*) and in Ausubel et al. (*supra*).

Genes encoding NEDG can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof which encodes NEDG. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA, or PNA, to the control regions of the gene encoding NEDG,

i.e., the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the 5 binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

10 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding NEDG.

15 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The 20 suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical 25 synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding NEDG. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

30 RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase

linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by 5 endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection and by liposome injections may be achieved using 10 methods which are well known in the art.

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a 15 pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of NEDG, antibodies to NEDG, mimetics, agonists, antagonists, or inhibitors of NEDG. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical 20 carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any 25 number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used 30 pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by 5 the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, 10 mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

15 Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

20 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty 25 oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl 30 cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or

triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of NEDG, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example NEDG or fragments thereof, antibodies of NEDG, agonists, antagonists or inhibitors of NEDG, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic

index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the 5 ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into 10 account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

15 Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or 20 their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind NEDG may be used for the diagnosis of conditions or diseases characterized by expression of NEDG, or in assays to monitor patients being treated with NEDG, agonists, antagonists or inhibitors. The antibodies useful for 25 diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for NEDG include methods which utilize the antibody and a label to detect NEDG in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in 30 the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring NEDG are known in the art and provide a basis for diagnosing altered or abnormal levels of NEDG expression.

Normal or standard values for NEDG expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to NEDG under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric means. Quantities of 5 NEDG expressed in subject, control and disease, samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding NEDG may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide 10 sequences, antisense RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of NEDG may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of NEDG, and to monitor regulation of NEDG levels during therapeutic intervention.

15 In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding NEDG or closely related molecules, may be used to identify nucleic acid sequences which encode NEDG. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the 20 stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding NEDG, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the NEDG encoding sequences. The 25 hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring NEDG.

Means for producing specific hybridization probes for DNAs encoding NEDG include the cloning of nucleic acid sequences encoding NEDG or NEDG derivatives into vectors for the 30 production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a

variety of reporter groups, for example, radionuclides such as 32P or 35S, or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding NEDG may be used for the diagnosis of disorders 5 which are associated with expression of NEDG. Examples of such conditions or diseases include, but are not limited to, cancers such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma and particularly cancers of the adrenal gland, bladder, bone, brain, breast, cervix, esophagus, gastrointestinal tract, heart, kidney, liver, lung, ovaries, pancreas, parathyroid, pituitary gland, prostate, salivary gland, spleen, stomach, thymus, thyroid, 10 testes, and uterus; disorders of cell growth and proliferation such as adult respiratory distress syndrome, allergies, ankylosing spondylitis, anovulation, aberrant corpus luteum formation, asthma, atherosclerosis, arteriosclerosis, bronchitis, dermatomyositis, diabetic retinopathy, hypereosinophilia, neurofibromatosis, polymyositis, rheumatoid arthritis, Alzheimer's disease, heart attacks, osteoarthritis, osteoporosis, Parkinson's disease, stroke, damage to cells such as 15 heart muscle, and nerve cells caused by ischemia, free radicals, and toxins; rheumatoid arthritis, wound healing. The polynucleotide sequences encoding NEDG may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dip stick, pin, ELISA or chip assays utilizing fluids or tissues from patient biopsies to detect altered NEDG expression. Such qualitative or quantitative methods are well known in the art.

20 In a particular aspect, the nucleotide sequences encoding NEDG may be useful in assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequences encoding NEDG may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated 25 and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding NEDG in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic 30 treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of

NEDG, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes NEDG, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the 5 values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays may 10 be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of a relatively high amount of transcript in biopsied 15 tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

20 Additional diagnostic uses for oligonucleotides designed from the sequences encoding NEDG may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced from a recombinant source. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'->3') and another with antisense (3'<-5'), employed under optimized conditions for identification of a specific gene or condition. The same 25 two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of NEDG include 30 radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) J. Immunol. Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format

where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In another embodiment of the invention, the nucleic acid sequences which encode NEDG may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. Such techniques include FISH, FACS, or artificial chromosome constructions, such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C.M. (1993) *Blood Rev.* 7:127-134, and Trask, B.J. (1991) *Trends Genet.*

10 7:149-154.

FISH (as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of *Science* (265:1981f). Correlation between the location of the 15 gene encoding NEDG on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques such 20 as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for 25 disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) *Nature* 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal 30 location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, NEDG, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of

drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between NEDG and the agent being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to NEDG large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with NEDG, or fragments thereof, and washed. Bound NEDG is then detected by methods well known in the art. Purified NEDG can also be 10 coated directly onto plates for use in the aforementioned drug screening techniques.

Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding NEDG specifically compete with a test compound for 15 binding NEDG. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with NEDG.

In additional embodiments, the nucleotide sequences which encode NEDG may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, 20 such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

EXAMPLES

I TLYMNOR01 cDNA Library Construction

25 The TLYMNOR01 cDNA library was constructed with RNA isolated from non-adherent peripheral blood mononuclear cells obtained from a 24-year-old Caucasian male. The cells were purified on Ficoll Hypaque, harvested, lysed in GuSCN, and spun through CsCl to obtain RNA for library construction. The RNA was primed with oligo dT and cDNA was synthesized from the mRNA. Double-stranded cDNA was blunted, ligated to EcoRI adaptors, digested with XbaI, 30 size-selected, and cloned into the XbaI and EcoRI sites of the Lambda UniZAP vector (Stratagene).

II Isolation and Sequencing of cDNA Clones

The phagemid forms of individual cDNA clones were obtained by the in vivo excision process, in which the host bacterial strain was coinfecte⁵d with both the lambda library phage and an f1 helper phage. Proteins derived from both the library-containing phage and the helper phage nicked the lambda DNA, initiated new DNA synthesis from defined sequences on the lambda target DNA and created a smaller, single stranded circular phagemid DNA molecule that included all DNA sequences of the pBluescript® plasmid and the cDNA insert. The phagemid DNA was secreted from the cells and purified, then used to re-infect fresh host cells, where the double stranded phagemid DNA was produced. Because the phagemid carries the gene for β-
10 lactamase, the newly-transformed bacteria are selected on medium containing ampicillin.

Phagemid DNA was purified using the QIAwell-8 QIAwell PLUS™, or QIAwell ULTRA™ DNA Purification System (QIAGEN Inc. Chatsworth CA). The DNA was eluted from the purification resin already prepared for DNA sequencing and other analytical manipulations.

15 The cDNA inserts from random isolates of the library were sequenced in part by the method of Sanger F and AR Coulson (1975; J Mol Biol 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno NV) in combination with four Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown MA) and Applied Biosystems 377 or 373 DNA Sequencing Systems (Perkin Elmer), and the reading frame was determined.

20

III Homology Searching of cDNA Clones and Their Deduced Proteins

The nucleotide sequences of the Sequence Listing or amino acid sequences deduced from them were used as query sequences against databases such as GenBank, SwissProt, BLOCKS, and Pima II. These databases which contain previously identified and annotated sequences were 25 searched for regions of homology (similarity) using BLAST, which stands for Basic Local Alignment Search Tool (Altschul, S.F. (1993) J. Mol. Evol. 36:290-300; Altschul et al. (1990) J. Mol. Biol. 215:403-410).

BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in 30 determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal or plant) origin. Other algorithms such as the one described in Smith RF and TF Smith (1992; Protein Engineering 5:35-51), incorporated herein by reference, can be

used when dealing with primary sequence patterns and secondary structure gap penalties. As disclosed in this application, the sequences have lengths of at least 49 nucleotides, and no more than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

The BLAST approach, as detailed in Karlin, S. and S.F. Altschul (1993; Proc Nat. Acad. Sci. 90:5893-3) and incorporated herein by reference, searches for matches between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. In this application, threshold was set at 10^{-25} for nucleotides and 10^{-14} for peptides.

Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and mammalian sequences (mam), and deduced amino acid sequences from the same clones are searched against GenBank functional protein databases, mammalian (mamp), vertebrate (vrtp) and eukaryote (eukp), for homology. The relevant database for a particular match were reported as a GIxxx±p (where xxx is pri, rod, etc and if present, p = peptide). Product score, the calculation of which is shown below, was used to determine the electronic stringency. For an exact match, product score was set at 70 with a conservative lower limit set at approximately 40 (1-2% error due to uncalled bases).

IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., supra).

Analogous computer techniques using BLAST (Altschul, S.F. 1993 and 1990, supra) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually

identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding NEDG occurs. Abundance and percent abundance are also reported. Abundance 5 directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

V Extension of NEDG-Encoding Polynucleotides

Nucleic acid sequence of Incyte clone 144690 or SEQ ID NO:2 is used to design 10 oligonucleotide primers for extending a partial nucleotide sequence to full length or for obtaining 5' or 3', intron or other control sequences from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers are used to facilitate the extension of the known sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the 15 region of interest. The initial primers are designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations is avoided.

20 The original, selected cDNA libraries, or a human genomic library are used to extend the sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary or desired, additional sets of primers are designed to further extend the known region.

By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of 25 each primer and the recommended concentrations of all other components of the kit, PCR is performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the following parameters:

Step 1	94° C for 1 min (initial denaturation)
Step 2	65° C for 1 min
30 Step 3	68° C for 6 min
Step 4	94° C for 15 sec
Step 5	65° C for 1 min
Step 6	68° C for 7 min
Step 7	Repeat step 4-6 for 15 additional cycles

Step 8	94° C for 15 sec
Step 9	65° C for 1 min
Step 10	68° C for 7:15 min
Step 11	Repeat step 8-10 for 12 cycles
5 Step 12	72° C for 8 min
Step 13	4° C (and holding)

A 5-10 μ l aliquot of the reaction mixture is analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in 10 extending the sequence. Bands thought to contain the largest products are selected and removed from the gel. Further purification involves using a commercial gel extraction method such as QIAQuick™ (QIAGEN Inc., Chatsworth, CA). After recovery of the DNA, Klenow enzyme is used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitate religation and cloning.

15 After ethanol precipitation, the products are redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase are added, and the mixture is incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) are transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook et al., supra). After incubation for one hour at 37° C, the whole 20 transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook et al., supra) containing 2x Carb. The following day, several colonies are randomly picked from each plate and cultured in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each 25 overnight culture is transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample is transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction are added to each well. Amplification is performed using the following conditions:

30 Step 1	94° C for 60 sec
Step 2	94° C for 20 sec
Step 3	55° C for 30 sec
Step 4	72° C for 90 sec
Step 5	Repeat steps 2-4 for an additional 29 cycles
35 Step 6	72° C for 180 sec
Step 7	4° C (and holding)

Aliquots of the PCR reactions are run on agarose gels together with molecular weight markers. The sizes of the PCR products are compared to the original partial cDNAs, and appropriate clones are selected, ligated into plasmid, and sequenced.

VI Labeling and Use of Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 μ Ci of [γ - 32 P] 10 adenosine triphosphate (Amersham) and T4 polynucleotide kinase (DuPont NEN $^{\circ}$, Boston, MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 superfine resin column (Pharmacia & Upjohn). A portion containing 10^7 counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, 15 Pst I, Xba I, or Pvu II; DuPont NEN $^{\circ}$).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% 20 sodium dodecyl sulfate. After XOMAT AR $^{\text{TM}}$ film (Kodak, Rochester, NY) is exposed to the blots in a Phosphoimager cassette (Molecular Dynamics, Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

VIII Complementary Polynucleotides

Sequence complementary to the NEDG-encoding sequence, or any part thereof, is used 25 to decrease or inhibit expression of naturally occurring NEDG. Although use of oligonucleotides comprising from about 15 to about 30 base-pairs is described, essentially the same procedure is used with smaller or larger sequence fragments. Appropriate oligonucleotides are designed using Oligo 4.06 software and the coding sequence of NEDG, SEQ ID NO:1. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to 30 prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the ABBR-encoding transcript.

VIII Expression of NEDG

Expression of NEDG is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector is used to express NEDG in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent 5 seven residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

Induction of an isolated, transformed bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first eight residues of β -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of 10 NEDG into the bacterial growth media which can be used directly in the following assay for activity.

IX Demonstration of NEDG Activity

Internal segments or cytoplasmic domains from an orphan G protein-coupled seven transmembrane receptor may be exchanged with the analogous domains of a known G protein-15 coupled seven transmembrane receptor and used to identify the G-proteins and downstream signaling pathways activated by the orphan receptor domains (Kobilka, B. K. et al (1988) *Science* 240:1310-1316). In an analogous fashion, domains of the orphan receptor may be cloned as a portion of a fusion protein and used in binding assays to demonstrate interactions with specific G proteins. Studies have shown that the third intracellular loop of G protein-coupled seven 20 transmembrane receptors are important for G protein interaction and signal transduction (Conklin, B. R. et al (1993) *Cell* 73:631-641). The DNA fragment corresponding to the third intracellular loop of NEDG may be amplified by the polymerase chain reaction (PCR) and subcloned into a fusion vector such as pGEX (Pharmacia Biotech). The construct is transformed into an appropriate bacterial host, induced, and the fusion protein is purified from the cell lysate 25 by glutathione-Sepharose 4B (Pharmacia) affinity chromatography.

For *in vitro* binding assays, cell extracts containing G proteins are prepared by extraction with 50 mM Tris, pH 7.8, 1 mM EGTA, 5 mM MgCl₂, 20 mM CHAPS, 20% glycerol, 10 μ g of both aprotinin and leupeptin, and 20 μ l of 50 mM phenylmethylsulfonyl fluoride. The lysate is incubated on ice for 45 min with constant stirring, centrifuged at 23,000 g for 15 min at 4 °C, and 30 the supernatant is collected. 750 μ g of cell extract is incubated with GST fusion protein beads for 2 h at 4 °C. The GST beads are washed five times with phosphate-buffered saline. Bound G subunits are detected by [³²P]ADP-ribosylation with pertussis or cholera toxins. The reactions

are terminated by the addition of SDS sample buffer (4.6% (w/v) SDS, 10% (v/v) -mercaptoethanol, 20% (w/v) glycerol; 95.2 mM Tris-HCl, pH 6.8, 0.01% (w/v) bromphenol blue). The [³²P]ADP-labeled proteins are separated on 10% SDS-PAGE gels, and autoradiographed. These gels are transferred to nitrocellulose paper, blocked with blotto (5% 5 nonfat dried milk, 50 mM Tris-HCl (pH 8.0), 2 mM CaCl₂, 80 mM NaCl, 0.02% NaN₃, and 0.2% Nonidet P-40) for 1 hour at room temperature, followed by incubation for 1.5 hours with G α subtype selective antibodies (1:500; Calbiochem-Novabiochem). After three washes, blots are 10 incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin (1:2000, Cappel, Westchester, PA) and visualized by the chemiluminescence-based ECL method (Amersham Corp.).

X Production of NEDG Specific Antibodies

NEDG that is substantially purified using PAGE electrophoresis (Sambrook, *supra*), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2 is analyzed using 15 DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (*supra*), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied 20 Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., *supra*). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for 25 antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

XI Purification of Naturally Occurring NEDG Using Specific Antibodies

Naturally occurring or recombinant NEDG is substantially purified by immunoaffinity chromatography using antibodies specific for NEDG. An immunoaffinity column is constructed by covalently coupling NEDG antibody to an activated chromatographic resin, such as 30 CnBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing NEDG is passed over the immunoaffinity column, and the column is

washed under conditions that allow the preferential absorbance of NEDG (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/NEDG binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and NEDG is collected.

5 XII Identification of Molecules Which Interact with NEDG

NEDG or biologically active fragments thereof are labeled with ^{125}I Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133:529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled NEDG, washed and any wells with labeled NEDG complex are assayed. Data obtained using different concentrations of NEDG are 10 used to calculate values for the number, affinity, and association of NEDG with the candidate molecules.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit 15 of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Au-Young, Janice
Guegler, Karl

(ii) TITLE OF THE INVENTION: EDG-1 LIKE RECEPTOR

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
(B) STREET: 3174 Porter Drive
(C) CITY: Palo Alto
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 94304

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) PCT APPLICATION NUMBER: To Be Assigned
(B) FILING DATE: Filed Herewith

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/845,566
(B) FILING DATE: 24-APR-1997

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Billings, Lucy J.
(B) REGISTRATION NUMBER: 36,749
(C) REFERENCE/DOCKET NUMBER: PF-0271 PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 650-855-0555
(B) TELEFAX: 650-845-4166

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 509 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: TYMNOR01
(B) CLONE: 144690

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Asn Ala Thr Gly Thr Pro Val Ala Pro Glu Ser Cys Gln Gln Leu
1 5 10 15
Ala Ala Gly Xaa His Ser Arg Leu Ile Xaa Leu His Tyr Asn His Ser
20 25 30
Gly Arg Leu Ala Gly Arg Gly Pro Glu Asp Gly Leu Gly Ala
35 40 45

Leu Arg Gly Leu Ser Val Ala Ala Ser Cys Leu Val Val Leu Glu Asn
 50 55 60
 Leu Leu Val Leu Ala Ala Ile Thr Ser His Met Arg Ser Arg Arg Trp
 65 70 75 80
 Val Tyr Tyr Cys Leu Val Asn Ile Thr Leu Ser Asp Leu Leu Thr Gly
 85 90 95
 Ala Ala Tyr Leu Ala Asn Val Leu Leu Ser Gly Ala Arg Thr Phe Arg
 100 105 110
 Leu Ala Pro Ala Gln Trp Phe Leu Arg Glu Gly Leu Leu Phe Thr Ala
 115 120 125
 Leu Ala Ala Ser Thr Phe Ser Leu Leu Phe Thr Ala Gly Glu Arg Phe
 130 135 140
 Ala Thr Met Val Arg Pro Val Ala Glu Ser Gly Ala Thr Lys Thr Ser
 145 150 155 160
 Arg Val Tyr Gly Phe Ile Gly Leu Cys Trp Leu Leu Ala Ala Leu Leu
 165 170 175
 Gly Met Leu Pro Leu Leu Gly Trp Asn Cys Leu Cys Ala Phe Asp Arg
 180 185 190
 Cys Ser Ser Leu Leu Pro Leu Tyr Ser Lys Arg Tyr Ile Leu Phe Cys
 195 200 205
 Leu Val Ile Phe Ala Gly Val Leu Ala Thr Ile Met Gly Leu Tyr Gly
 210 215 220
 Ala Ile Phe Arg Leu Val Gln Ala Ser Gly Gln Lys Ala Pro Arg Pro
 225 230 235 240
 Ala Ala Arg Arg Lys Ala Arg Arg Leu Leu Lys Thr Val Leu Met Ile
 245 250 255
 Leu Leu Ala Phe Leu Val Cys Trp Gly Pro Leu Phe Gly Ala Ala Ala
 260 265 270
 Gly Arg Arg Leu Trp Leu Gln Pro Leu Gly Pro Gly Val Pro Ala Gly
 275 280 285
 His Gly Leu Asp Pro Gly Pro Gly Arg Pro Gln Leu Gly Gly Gln Pro
 290 295 300
 His His Leu Leu Leu Pro Gln Gln Gly Val Gln Ser Arg Ala Gln
 305 310 315 320
 Pro Ser Ser Ala Ala Gly Val Ser Gly Trp Ala Cys Glu Gly Pro Gly
 325 330 335
 Asp Cys Leu Ala Arg Ala Val Glu Ala His Ser Gly Ala Ser Asn His
 340 345 350
 Arg Gln Leu Ser Glu Ala Lys Gly Gln Leu Ser Arg Leu Pro Leu Ala
 355 360 365
 Gln Leu Ser Asp Ala Gly Ala Pro Val Gln His Leu Gln Arg Ala Glu
 370 375 380
 Ile Leu Lys Leu Gln Ser Cys Val Trp Met Val Gln Pro Pro Gly Ala
 385 390 395 400
 Cys Gln Ala Gly Pro Pro Gly Val Gln Glu Ala Val Cys Thr Gln Pro
 405 410 415
 Ser Pro Val Trp Gly Ala Gly Asn Gly Thr Gly Pro His Gly Leu Pro
 420 425 430
 Gly Gly Leu Ser Gly Leu Leu Thr Pro Asn Gly Leu Pro Met Val Thr
 435 440 445
 Leu Asp Lys Glu Ala Thr Thr Pro Pro Pro Arg Thr Ser Arg Glu His
 450 455 460
 Pro Gly Val Gly Ala Ser Gly Phe Pro Thr Thr Pro Leu Leu Cys Asp
 465 470 475 480
 Ser Gly Glu Val Pro Ala Pro Leu Trp Ala Ser Val Gly Leu Pro Gly
 485 490 495
 Cys Lys Gly Trp Thr Val Gly Cys Met Pro Trp Gln His
 500 505

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1649 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: TYMNOR01
- (B) CLONE: 144690

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

G	GGGAGGCCA	TGAACGCCAC	GGGGACCCCG	GTGGCCCCG	AGTCCTGCCA	ACAGCTGGCG	60
G	CCGGCNGGC	ACAGCCGGCT	CATTGNTCTG	CACTACAACC	ACTCGGGCCG	GCTGGCCGG	120
C	CGCGGGGGC	CGGAGGATGG	CGGCGTGGGG	GCCCTGCGGG	GGCTGTCGGT	NGCCGCCAGC	180
T	TGCCTGGTGG	TGCTGGAGAA	CTTGCCTGGTG	CTGGCGGCCA	TCACCAGCCA	CATGCGGTGCG	240
C	CGACGCTGGG	TCTACTATTG	CCTGGTGAAC	ATCACGCTGA	GTGACCTGCT	CACGGGCGCG	300
G	GCCTACCTGG	CCAAAGTGCT	GCTGTGCGGG	GCCCGCACCT	TCCGTCTGGC	GCCCGCCAG	360
T	TGGTTCTAC	GGGAGGGCCT	GCTCTTCACC	GCCCTGGCCG	CCTCCACCTT	CAGCCTGCTC	420
T	TTCACTCGAG	GGGAGCGCTT	TGCCACATG	GTGCGGGCCG	TGGCGAGAG	CGGGGCCACC	480
A	AAGACCAGC	GGCTCTACGG	CTTCATCGGC	CTCTGCTGGC	TGCTGGCCGC	GCTGCTGGGG	540
A	ATGCTGCCCT	TGCTGGCTG	GAACGTGCTG	TGCGCCTTTG	ACCGCTGCTC	CAGCCTTCCTG	600
C	CCCCTCTACT	CCAAAGCGCTA	CATCCTCTTC	TGCCTGGTGA	TCTTCGCCGG	CGTCCTGGCC	660
A	ACCATCATGG	GCCTCTATGG	GGCCATCTTC	CGCCTGGTGC	AGGCCAGCGG	GCAGAAGGCC	720
C	CCACGCCAG	CGGGCCGCCG	CAAGGCCCGC	CGCCTGCTGA	AGACGGTGC	GATGATCCTG	780
C	CTGGCCTTCC	TGGTGTGCTG	GGGCCCACTC	TTCGGGGCTG	CTGCTGGCCG	ACGTCTTTGG	840
C	CTCCAACCTC	TGGGCCAGG	AGTACCTGCG	GGGCATGGAC	TGGATCCTGG	CCCTGGCCGT	900
C	CCTCAACTCG	GGGGTCAACC	CCATCATGTA	CTCCTTCCCG	AGCAGGGAGG	TGTGCAGAGC	960
C	CGTGCTCAGC	CTTCTCTGTC	TGCGGGTGTG	TCCGGCTGGG	CATGCGAGGG	CCCGGGGGAC	1020
T	TGCCTGGCCC	GGGGCGTCGA	GGCTCACTTC	GGAGCTTCCA	ACCACCGACA	GCTCTCTGAG	1080
G	GCCAAGGGAC	AGCTTTCGCG	GCTCCCGCTC	GCTCAGCTT	CGGATGCGGG	AGCCCCCTGTC	1140
C	CAGCATCTCC	ACCGTGCAGGA	GATTCTGAAG	TTGCAGTCTT	GGTGTGGAT	GGTGCAGCCA	1200
C	CCGGGTGCGT	GCCAGGCAGG	CCCTCTGGG	GTACAGGAAG	CTGTGTGCAC	GCAGCCCTCG	1260
C	CCTGTATGGG	GAGCAGGGAA	CGGGACAGGC	CCCCATGGTC	TTCCCGGTGG	CCTCTCGGGG	1320
C	CTTCTGACGC	CAAATGGCT	TCCCATGGTC	ACCCCTGGACA	AGGAGGCAAC	CACCCCACCT	1380
C	CCCCGTACGA	GCAGAGACCA	CCCTGGTGTG	GGGGCAGTG	GGTCCCCAC	AACCCCGCTT	1440
C	CTGTGTGATT	CTGGGAAAGT	CCCCGGCCCT	CTCTGGCCCT	CAGTAGGGCT	CCCAGGCTGC	1500
A	AAGGGGTGGA	CTGTGGGATG	CATGCGCTGG	CAACATTGAA	GTTTNGATTA	ATGGTANCCT	1560
G	GAAAANCNT	AGGTGGTANA	NAANAANNGG	GGGGNCCNTT	TANAGGGTCC	AAAGTTAATT	1620
T	TANCGGTGNA	TGCGNGGTTN	TNNGTNTTT				1649

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 381 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 181948

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met	Gly	Pro	Thr	Ser	Val	Pro	Leu	Val	Lys	Ala	His	Arg	Ser	Ser	Val
1						5		10							15
Ser	Asp	Tyr	Val	Asn	Tyr	Asp	Ile	Ile	Val	Arg	His	Tyr	Asn	Tyr	Thr
							20		25						30
Gly	Lys	Leu	Asn	Ile	Ser	Ala	Asp	Lys	Glu	Asn	Ser	Ile	Lys	Leu	Thr
							35		40						45
Ser	Val	Val	Phe	Ile	Leu	Ile	Cys	Cys	Phe	Ile	Ile	Leu	Glu	Asn	Ile
							50		55						60
Phe	Val	Leu	Leu	Thr	Ile	Trp	Lys	Thr	Lys	Lys	Phe	His	Arg	Pro	Met
							65		70						80
Tyr	Tyr	Phe	Ile	Gly	Asn	Leu	Ala	Leu	Ser	Asp	Leu	Leu	Ala	Gly	Val
							85		90						95
Ala	Tyr	Thr	Ala	Asn	Leu	Leu	Ser	Gly	Ala	Thr	Thr	Tyr	Lys	Leu	
							100		105						110

Thr Pro Ala Gln Trp Phe Leu Arg Glu Gly Ser Met Phe Val Ala Leu
115 120 125
Ser Ala Ser Val Phe Ser Leu Leu Ala Ile Ala Ile Glu Arg Tyr Ile
130 135 140
Thr Met Leu Lys Met Lys Leu His Asn Gly Ser Asn Asn Phe Arg Leu
145 150 155 160
Phe Leu Leu Ile Ser Ala Cys Trp Val Ile Ser Leu Ile Leu Gly Gly
165 170 175
Leu Pro Ile Met Gly Trp Asn Cys Ile Ser Ala Leu Ser Ser Cys Ser
180 185 190
Thr Val Leu Pro Leu Tyr His Lys His Tyr Ile Leu Phe Cys Thr Thr
195 200 205
Val Phe Thr Leu Leu Leu Ser Ile Val Ile Leu Tyr Cys Arg Ile
210 215 220
Tyr Ser Leu Val Arg Thr Arg Ser Arg Arg Leu Thr Phe Arg Lys Asn
225 230 235 240
Ile Ser Lys Ala Ser Arg Ser Ser Glu Asn Val Ala Leu Leu Lys Thr
245 250 255
Val Ile Ile Val Leu Ser Val Phe Ile Ala Cys Trp Ala Pro Leu Phe
260 265 270
Ile Leu Leu Leu Asp Val Gly Cys Lys Val Lys Thr Cys Asp Ile
275 280 285
Leu Phe Arg Ala Glu Tyr Phe Leu Val Leu Ala Val Leu Asn Ser Gly
290 295 300
Thr Asn Pro Ile Ile Tyr Thr Leu Thr Asn Lys Glu Met Arg Arg Ala
305 310 315 320
Phe Ile Arg Ile Met Ser Cys Cys Lys Cys Pro Ser Gly Asp Ser Ala
325 330 335
Gly Lys Phe Lys Arg Pro Ile Ile Ala Gly Met Glu Phe Ser Arg Ser
340 345 350
Lys Ser Asp Asn Ser Ser His Pro Gln Lys Asp Glu Gly Asp Asn Pro
355 360 365
Glu Thr Ile Met Ser Ser Gly Asn Val Asn Ser Ser Ser
370 375 380

What is claimed is:

1. A substantially purified edg-1 like receptor (NEDG) comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.
2. An isolated and purified polynucleotide sequence encoding the edg-1 like receptor of claim 1.
3. A hybridization probe comprising the polynucleotide sequence of claim 2.
4. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or variants thereof.
5. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 2 or variants thereof.

10

6. A hybridization probe comprising the polynucleotide sequence of claim 5.
7. An expression vector containing the polynucleotide sequence of claim 2.
8. A host cell containing the vector of claim 7.
9. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 the method comprising the steps of:

15

- a) culturing the host cell of claim 9 under conditions suitable for the expression of the polypeptide; and
- b) recovering the polypeptide from the host cell culture.

10. A pharmaceutical composition comprising a substantially purified edg-1 like receptor having the amino acid sequence of claim 1 in conjunction with a suitable pharmaceutical carrier.

20

11. A purified antibody which binds specifically to the polypeptide of claim 1.
12. A purified agonist which modulates the activity of the polypeptide of claim 1.
13. A purified antagonist which inhibits the activity of the polypeptide of claim 1.

25

14. A pharmaceutical composition comprising the antagonist of claim 13 in conjunction with a suitable pharmaceutical carrier.

15. A method for stimulating cell proliferation comprising administering to a subject in need of such treatment an effective amount of the protein of claim 1.

30

16. A method for treating a disorder of abnormal cell growth and differentiation comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 10.

17. A method for treating a disorder of excessive cell proliferation comprising

administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 14.

18. A method for detection of a polynucleotide encoding edg-1 like receptor in a biological sample comprising the steps of:

5 a) hybridizing the polynucleotide of claim 6 to nucleic acid material of a biological sample, thereby forming a hybridization complex: and
b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding edg-1 like receptor-like protein in said biological sample.

10

9	18	27	36	45	54
GGG GAG GCC ATG AAC GCC ACG GGG ACC CCG GTG GCC CCC GAG TCC TGC CAA CAG	M N A T G T P V A P E S C Q Q				
63	72	81	90	99	108
CTG GCG GCC GGC NGG CAC AGC CGG CTC ATT GNT CTG CAC TAC AAC CAC TCG GGC	L A G X H S R L I X L H Y N H S G				
117	126	135	144	153	162
CGG CTG GCC GGG CGC GGG CCG GAG GAT GGC CTG GGC CTG CGG CGG	R L A G R G P E D G G L G A L R G				
171	180	189	198	207	216
CTG TCG GTN GCC GCC AGC TGC CTG GTC GTC GAG AAC TGC CTG GTG CTG CGG	L S V A A S C L V V L E N L L V L A				
225	234	243	252	261	270
GCC ATC ACC AGC CAC ATG CGG TCG CGA CGC TGG GTC TAC TAT TGC GTG AAC	A I T S H M R S R R W V Y C L V N				
279	288	297	306	315	324
ATC ACG CTG AGT GAC CTG CTC ACG GGC GCG GCC TAC CTG GCC AAC GTG CTG CTG	I T L S D L L T G A A Y L A N V L L				
333	342	351	360	369	378
TCG GGG GCC CGC ACC TTC CGT CTG GCG CCC GCC CAG TGG TTC CTA CGG GAG GGC	S G A R T F R L A P A Q W F L R E G				

FIGURE 1A

2/9

387	CTG	CTC	TTC	ACC	GCC	CTG	GCC	TCC	ACC	TTC	AGC	CTG	CTC	TTC	ACT	GCA	GGG
L	L	F	T	A	L	A	A	S	T	F	S	L	L	F	T	A	G
441	GAG	CGC	TTT	GCC	ACC	ATG	GTG	CGG	CGG	GTG	GCC	GAG	AGC	GGG	GCC	ACC	AAG
E	R	F	A	T	M	V	R	P	V	A	E	S	G	A	T	K	T
495	AGC	CGC	GTC	TAC	GGC	TTC	ATC	GGC	CTC	TGC	TGG	CTG	CTG	GCG	CTG	CTG	GGG
S	R	V	Y	G	F	I	G	L	C	W	L	L	A	A	L	L	G
549	ATG	CTG	CCT	TTG	CTG	GGC	TGG	AAC	TGC	CTG	TGC	GCC	TTT	GAC	CGC	TGC	TCC
M	L	P	L	L	G	W	N	C	L	C	A	F	D	R	C	S	S
603	CTT	CTG	CCC	CTC	TAC	TCC	AAG	CGC	TAC	ATC	CTC	TTC	TGC	CTG	ATC	TTC	GCC
L	L	P	L	Y	S	K	R	Y	I	L	F	C	L	V	I	F	A
657	GGC	GTC	GCC	ACC	ATC	ATG	GGC	CTC	TAT	GGG	GCC	ATC	TTC	CGC	CTG	GTG	CAG
G	V	L	A	T	I	M	G	L	Y	G	A	I	F	R	L	V	Q
711	GCC	AGC	GGG	CAG	AAG	GCC	CCA	CGC	CCA	GCG	GCC	CGC	CGC	AAG	GCC	CGC	CTG
A	S	G	Q	K	A	P	R	P	A	A	R	R	R	K	A	R	L

FIGURE 1B

3/9

765	CTG	AAG	ACG	GTG	CTG	ATG	ATC	CTG	CAG	CTG	CTG	783	792	801	810
L	K	T	V	L	M	I	L	L	A	F	L	TTC	TGG	GGC	CCA
F	G	A	A	G	R	R	L	W	Q	P	V	C	W	G	CTC
819	TTC	GGG	GCT	GCT	GGC	CGA	CGT	CTT	TGG	CTC	CAA	846	855	864	
P	A	G	H	G	L	D	P	G	R	P	L	Q	G	P	G
873	CCT	GCG	GGG	CAT	GGA	CTG	GAT	CCT	GGC	CCT	CGT	900	909	918	
P	A	G	H	G	L	D	P	G	R	P	Q	L	G	G	CAA
927	CCC	CAT	CTA	CTC	CTT	CCG	CAG	CAG	GGG	GGT	GTG	945	954	963	972
P	H	L	L	L	P	Q	Q	G	G	G	V	Q	S	R	CCT
981	TCC	TCT	GCT	GCT	GTC	TCC	GGC	TGG	GCA	TGC	GAG	999	1008	1017	1026
S	S	A	A	G	V	S	G	W	A	C	E	G	P	G	CTG
1035	GCC	CGG	GCC	GTC	GAG	GCT	CAC	TCC	GGA	GCT	TCC	1053	1062	1071	1080
A	R	A	V	E	A	H	S	G	A	A	S	N	H	R	TCT
1089	GCC	AAG	GGA	CAG	CCT	TCG	CGG	CTC	CGT	CAG	CTC	1107	1116	1125	1134
A	K	G	Q	L	S	R	L	P	L	A	Q	L	S	D	G

FIGURE 1C

4/9

1143	1152	1161	1170	1179	1188
CCT GTC CAG CAT CTC CAG CGT GCG GAG ATT CTG AAG TTT CAG TCT TGC TGT	P V Q H L Q R A E I L K L Q S C V W				
1197	1206	1215	1224	1233	1242
ATG GTG CAG CCA CCG GGT GCG TGC CAG GCA GGC CCT CCT GGG GTA CAG GAA GCT	M V Q P P G A C Q A G P P G V Q E A				
1251	1260	1269	1278	1287	1296
GTG TGC ACG CAG CCC TCG CCT GTA TGG GGA GCA AAC GGG ACA GGC CCC CAT	V C T Q P S P V W G A G N G T G P H				
1305	1314	1323	1332	1341	1350
GGT CTT CCC GGT GGC CTC TCG GGG CTT CTG ACG CCA AAT GGG CTT CCC ATG GTC	G L P G L S G L T P N G L P M V				
1359	1368	1377	1386	1395	1404
ACC CTG GAC AAG GAG GCA ACC ACC CCA CCT CCC CGT ACG AGC AGA GAG CAC CCT	T L D K E A T T P P R T S R E H P				
1413	1422	1431	1440	1449	1458
GGT GTG GGG GCG AGT GGG TTC CCC ACA ACC CCG CTT CTG TGT GAT TCT GGG GAA	G V G A S G F P T P L L C D S G E				
1467	1476	1485	1494	1503	1512
GTC CCG GCC CCT CTC TGG GCC TCA GTA GGG CTC CCA GGC TGC AAG GGG TGG ACT	V P A P L W A S V G L P G C K G W T				

FIGURE 1D

1521 1530 1539 1548 1557 1566
GTG GGA TGC ATG CCC TGG CAA CAT TGA AGT TTN GAT TAA TGG TAN CGT GAA AAN
V G C M P W Q H

1575 1584 1593 1602 1611 1620
NCN TAG GTG GTA NAN AAN AAN NGG GGG GNC CNT TTA NAG GGT CCA AAG TTA ATT

1629 1638 1647
TAN CGG TGN ATG CGN GGT TNT NNG TNT TT

FIGURE 1E

6 / 9

FIGURE 2A

314	GVOSRAOPSSAAGVSGWAC	EGPGDC	CLARAVEAHSGASSNHR	144690	
280	CKVKT	-	-	-	
354	OLSEAKGOLSRLLPLAOLSDAGA	PVOHLQRAEILKLOSSCVW	144690		
294	-	-YFLVLA	VILNSGNTNPIIYTTLTNKEMR	-RAFIR	GI 181949
394	MVOOPPGACOAGPPGVQEAV	CTOPSPVWAGANGTGP	HGLPG	144690	
324	IM	-	-SC	-	-
434	GLSGLLTPNGLPMVTLDKEAT	TPPPRTSREHPGVGASGFP	144690		
334	DSAGKFKRPIIAGMEEFSRSKS	DNSSSHPKDE	-	-	
474	TTPLLCDSGEV	PAPLWASVGLPGCKGWTVGCM	PWQH	144690	
365	-	-GDNPE	ETIMSSGNVNSSS	GI 181949	

FIGURE 2B

8/9




FIGURE 3A




FIGURE 3B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/07830

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 A61K38/17 C07K16/28 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data bases consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL - EMEST11 Entry MM1170779, Acc.No. AA254425, 18 March 1997</p> <p>MARRA, M., ET AL.: "va16c04.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 723078 5'." XP002069462</p> <p>see the whole document</p> <p>---</p> <p>-/-</p>	5,6

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

- "Z" document member of the same patent family

Date of the actual completion of the international search

30 June 1998

Date of mailing of the international search report

20.07.98

Name and mailing address of the IBA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 ope nl,
 Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

1

INTERNATIONAL SEARCH REPORT

Int. application No.
PCT/US 98/07830

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 15-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/07830

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ADAMS, M.D. ET AL.: "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence."</p> <p>NATURE, vol. 377, no. Suppl., 28 September 1995, pages 3-174, XP002069461 see the whole document</p> <p>-& DATABASE EMBL - EMEST11 Entry HSZZ58293, Acc.No. AA353166, 18 April 1997</p> <p>ADAMS, M.D. ET AL.: "EST61259 Activated T-cells XX Homo sapiens cDNA 5' end." XP002069463 see the whole document</p> <p>---</p>	5,6
A	<p>YAMAGUCHI, F. ET AL.: "Molecular cloning of the novel human G protein-coupled receptor (GPCR) gene mapped on chromosome 9."</p> <p>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 227, 1996, pages 608-614, XP002069460 see figure 1</p> <p>---</p>	1-9,18
A	<p>WO 97 00952 A (INCYTE PHARMA INC) 9 January 1997 see the whole document, especially the claims.</p> <p>---</p>	
A	<p>US 5 585 476 A (MACLENNAN ALEXANDER J) 17 December 1996 see column 1, line 26 - column 2, line 2 see column 2, line 39 - line 49</p> <p>-----</p>	15,16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/07830

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9700952 A	09-01-1997	AU 6388696 A EP 0840787 A	22-01-1997 13-05-1998
US 5585476 A	17-12-1996	NONE	